Immedica Pharma AB
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Immedica Pharma AB - overview
Established
2018
Location
Stockholm, -, Sweden
Primary Industry
Pharmaceuticals
About
Based in Stockholm, Sweden, and founded in 2018, Immedica Pharma AB operates as a provider of therapies for rare diseases and specialty care services. In April 2024, KKR agreed to acquire Immedica Pharma AB from Impilo. As part of the transaction, Impilo will re-invest in the company. As of 2024, the company is led by its CEO, Anders Edvell, Ph.
D. The company provides a wide range of therapeutic solutions for various diseases, such as genetic and metabolic diseases, hematology and oncology treatments, and specialty care services. Moreover, the firm offers compliance, pharmacovigilance, quality assurance, regulatory, and market access services. Additionally, the firm also provides services such as patient safety initiatives, sustainable organization, and business operations.
The company plans to use its proceeds from April 2024 funding to launch the ultra-orphan drug Loargys into the market.
Current Investors
Impilo
Primary Industry
Pharmaceuticals
Sub Industries
Specialty Pharmaceuticals
Website
www.immedica.com/en/
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Immedica Pharma AB - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 49,475 | 9,222,320 | 16,166,005 | 18,898,387 | 30,675,092 | 42,898,343 | 64,949,427 | 84,802,000 | 255,292,000 | 417,959,000 | 494,968,000 | - | - | - |
| % Revenue Growth (YoY) | - | 18540.4% | 75.3% | 16.9% | 62.3% | 39.8% | 51.4% | 30.6% | 201.0% | 63.7% | 18.4% | - | - | - |
| EBITDA (USD) | (1,655,305) | (727,743) | 1,080,228 | (2,648,526) | 1,831,285 | 1,148,902 | 4,659,349 | (11,063,000) | (15,423,000) | 176,350,000 | 164,034,000 | - | - | - |
| Operating Income (USD) | (1,658,273) | (735,318) | 1,059,373 | (2,703,165) | 1,795,573 | 1,117,246 | 4,622,441 | (12,316,000) | (43,862,000) | 129,766,000 | 96,342,000 | - | - | - |
| Operating Margin | (3351.7%) | (8.0%) | 6.6% | (14.3%) | 5.9% | 2.6% | 7.1% | (14.5%) | (17.2%) | 31.0% | 19.5% | - | - | - |
| % EBITDA Margin | (3345.7%) | (7.9%) | 6.7% | (14.0%) | 6.0% | 2.7% | 7.2% | (13.0%) | (6.0%) | 42.2% | 33.1% | - | - | - |
| NET Income (USD) | (1,658,473) | (851,530) | 956,016 | 29,276,083 | 1,684,724 | 5,925,941 | 3,802,623 | (35,617,000) | (102,545,000) | 102,194,000 | 59,687,000 | - | - | - |
| % Net Margin | (3352.1%) | (9.2%) | 5.9% | 154.9% | 5.5% | 13.8% | 5.9% | (42.0%) | (40.2%) | 24.5% | 12.1% | - | - | - |
Immedica Pharma AB - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Public to Private, Trade Sale | Completed | Marinus Pharmaceuticals, Inc. | - | ||||||||
| Secondary Buyout | Completed | Immedica Pharma AB | - | ||||||||
| Company Formation | Completed | Immedica Pharma AB | - | ||||||||
| Add-on | Completed | Medical Need Europe AB | - |
Displaying 1 - 4 of 4
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.